Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI
Release Date: 08/10/2026
Smart Hearing Aids Hearing Loss and Cognitive Decline with Dr. Rachel Artsma Hear.com TRANSCRIPT
Empowered Patient Podcast
Dr. Rachel Artsma, lead audiologist at hear.com offers comprehensive hearing care services and she emphasizes how dramatically hearing aids have evolved from earlier generations. Bluetooth connectivity, rechargeable batteries, and real-time environmental adjustments are now being driven by smart chips in the devices, which also allow direct streaming of phone calls, music, and driving directions. Untreated hearing loss can lead to auditory deprivation, in which the brain does not receive clear auditory input, resulting in increased cognitive strain and a decline in cognitive function. Rachel...
info_outline
Smart Hearing Aids Hearing Loss and Cognitive Decline with Dr. Rachel Artsma Hear.com
Empowered Patient Podcast
Dr. Rachel Artsma, lead audiologist at hear.com offers comprehensive hearing care services and she emphasizes how dramatically hearing aids have evolved from earlier generations. Bluetooth connectivity, rechargeable batteries, and real-time environmental adjustments are now being driven by smart chips in the devices, which also allow direct streaming of phone calls, music, and driving directions. Untreated hearing loss can lead to auditory deprivation, in which the brain does not receive clear auditory input, resulting in increased cognitive strain and a decline in cognitive function. Rachel...
info_outline
Parkinson’s Disease Management Transformed by AI-Powered Longitudinal Tracking with Amy Gordon Franzen Rune Labs TRANSCRIPT
Empowered Patient Podcast
Amy Gordon Franzen, CEO of Rune Labs, developed StrivePD, a patient-facing app that supports those with Parkinson's disease by passively tracking their movements and collecting longitudinal data on tremor, gait, and activity patterns. The technology addresses a critical gap in neurodegenerative disease management by providing continuous, objective data that enables patients and clinicians to make more informed treatment decisions. There is also an AI chatbot that allows patients to interrogate their data and receive personalized insights while enabling clinicians and drug developers to...
info_outline
Parkinson’s Disease Management Transformed by AI-Powered Longitudinal Tracking with Amy Gordon Franzen Rune Labs
Empowered Patient Podcast
Amy Gordon Franzen, CEO of Rune Labs, developed StrivePD, a patient-facing app that supports those with Parkinson's disease by passively tracking their movements and collecting longitudinal data on tremor, gait, and activity patterns. The technology addresses a critical gap in neurodegenerative disease management by providing continuous, objective data that enables patients and clinicians to make more informed treatment decisions. There is also an AI chatbot that allows patients to interrogate their data and receive personalized insights while enabling clinicians and drug developers to...
info_outline
Gene Therapy for Treating Root Cause of Severe Food Allergies with Dr. Sid Kerkar AllerGene AI TRANSCRIPT
Empowered Patient Podcast
Dr. Sid Kerkar, CEO and Founder of AllerGene AI Therapeutics, is developing in vivo gene therapy for severe food allergies, where symptoms are currently treated rather than root causes. AllerGene AI is targeting mast cells, which are immune cells responsible for triggering allergic reactions, and their approach represents a significant opportunity to prevent these reactions. Unlike traditional cell therapy, this technology modifies cells within the body to recognize and eliminate armed mast cells, allowing the body to repopulate with non-reactive cells, preventing severe allergic reactions...
info_outline
Gene Therapy for Treating Root Cause of Severe Food Allergies with Dr. Sid Kerkar AllerGene AI
Empowered Patient Podcast
Dr. Sid Kerkar, CEO and Founder of AllerGene AI Therapeutics, is developing in vivo gene therapy for severe food allergies, where symptoms are currently treated rather than root causes. AllerGene AI is targeting mast cells, which are immune cells responsible for triggering allergic reactions, and their approach represents a significant opportunity to prevent these reactions. Unlike traditional cell therapy, this technology modifies cells within the body to recognize and eliminate armed mast cells, allowing the body to repopulate with non-reactive cells, preventing severe allergic reactions...
info_outline
Virtual Transitionist Model Reduces Complications after Acute Care Events with Dr. David Feldman Dimer Health TRANSCRIPT
Empowered Patient Podcast
Dr. David Feldman is the Chief Medical Officer at Dimer Health, a virtual care medical practice designed to improve patient outcomes during the critical 1-3 days following hospital discharge, outpatient surgery, or emergency room visits. The company addresses the gap in post-acute care between hospital care and primary care follow-up by proactive monitoring, medication management, and pain control. Inspired by the hospitalist model, Dimer is defining a transitionist model that is tailored to each patient's needs and home environment, intervening early on minor complications to reduce...
info_outline
Virtual Transitionist Model Reduces Complications after Acute Care Events with Dr. David Feldman Dimer Health
Empowered Patient Podcast
Dr. David Feldman is the Chief Medical Officer at Dimer Health, a virtual care medical practice designed to improve patient outcomes during the critical 1-3 days following hospital discharge, outpatient surgery, or emergency room visits. The company addresses the gap in post-acute care between hospital care and primary care follow-up by proactive monitoring, medication management, and pain control. Inspired by the hospitalist model, Dimer is defining a transitionist model that is tailored to each patient's needs and home environment, intervening early on minor complications to reduce...
info_outline
Certified Drug Label Translations in 26 Languages for Limited English Proficient Patients with Sharon Blank RxTran TRANSCRIPT
Empowered Patient Podcast
Sharon Blank, CEO of RxTran, highlights the value of certified translations of prescription dosing instructions in 26 languages to ensure that limited-English-proficient patients can understand dosing and medication risks. The organization works with pharmacies to deliver translations created by native-speaking pharmacists rather than by automated systems or untrained interpreters. As this LEP population grows, RxTran advocates for standardized, human-verified translation practices to ensure healthcare access and patient safety across all populations. Sharon explains, "So RxTran’s...
info_outline
Certified Drug Label Translations in 26 Languages for Limited English Proficient Patients with Sharon Blank RxTran
Empowered Patient Podcast
Sharon Blank, CEO of RxTran, highlights the value of certified translations of prescription dosing instructions in 26 languages to ensure that limited-English-proficient patients can understand dosing and medication risks. The organization works with pharmacies to deliver translations created by native-speaking pharmacists rather than by automated systems or untrained interpreters. As this LEP population grows, RxTran advocates for standardized, human-verified translation practices to ensure healthcare access and patient safety across all populations. Sharon explains, "So RxTran’s...
info_outlineVin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes.
Vin explains, "We are in the AI innovator category, and we're applying our proprietary platform to the challenges that exist in the world of drug development for pharmaceutical and biotech companies. Primarily our focus is on the first and the last stage of that process. So the first stage is what you call drug target discovery. So when you take a medication, it targets something in your body. So we're trying to identify novel targets that we believe are the root cause of certain diseases. And then we are also focused on the final stage, which is phase three clinical trials. That's where we have our experience. And that's obviously a very critical and pivotal point in the process and the final stage of a long 10- to 15-year, one- to two-billion-dollar drug development process."
"You need to have the right tool for a certain problem and then data, and they go together. I think on the data side, getting access to rich, deep data sets is critical. And fortunately, the cost to generate that type of data has come down pretty significantly over the past, say, 10 years. So now, for example, we have a project where we have brain data, and it's the type of data where you can really make discoveries and insights and so forth. And so that's a really critical part of this process. The other part is: what tool do you have, and what problem are you trying to solve? Our technology is unique. I'd say most companies use technology that comes from NVIDIA and AWS. So they're all kind of using the same tools from the same toolbox."
"Our technology comes from Johns Hopkins University Applied Physics Lab, which is a world-renowned institution. We have IP around our platform, and we've continued to innovate over the years. It definitely has unique capabilities, and it is specifically designed for the types of problems that exist in drug development."
#BullFrogAI $BFRG, #AI, #AIinBiotech, #MachineLearning, #DrugDevelopment #AIinHealthcare #PrecisionMedicine #Neuropsychiatry #Oncology #DigitalHealth #ClinicalTrials #Biomarkers #bfLEAP
